MAPT and Cognitive impairment: First, we evaluated a comprehensive panel of blood-based biomarkers to screen for tau-PET positivity in two memory clinic-based cohorts (BioFINDER-2 and TRIAD) in patients with subjective cognitive decline, mild cognitive impairment, or any form of dementia.